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ObjectiveaaOur aim was to evaluate the changes in blood glucose control and lipid profiles after 2-months of smoking cessation in 
healthy males.
MethodsaaSmoking abstinence was evaluated through self-report and urine cotinine levels. 12 individuals who succeeded in quitting 
smoking were analyzed. Fasting values of glucose and insulin were used to estimate the β-cell activity and insulin resistance was evaluat-
ed using the Homeostasis Model Assessment (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI). 
ResultsaaThe data showed that the subjects had a significant increase in weight, body mass index and fasting plasma glucose levels after 
smoking cessation. The HOMA-Insulin Resistance and the HOMA β-cell function increased significantly (p=0.005, p=0.047 respectively). 
The QUICKI showed a significant decrease (p=0.005). In addition, the low-density lipoprotein cholesterol levels decreased significantly 
(p=0.028); however, changes in the high-density lipoprotein cholesterol, the triglyceride and total cholesterol levels were not significant 
(p=0.284, p=0.445 respectively).
ConclusionaaDuring the initial stage of smoking abstinence, insulin resistance increased and insulin sensitivity decreased due to ele-
vated body weight and fat composition. Therefore, it is important to educate individuals that stop smoking about the necessity of weight 
control during smoking cessation programs.  Psychiatry Investig 2011;8:149-154
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INTRODUCTION
Smoking is known to negatively impact human health. Car-
cinogenic processes, vasomotor dysfunction, impaired endo-
thelial-dependent vasodilatation, and the modification of lip-
id profiles are included in these adverse effects.
1,2 Cigarette 
smoking has been clearly identified as an independent, major 
risk factor for atherosclerosis and coronary heart disease 
(CHD)
3-5 and myocardial infarction.
6 There is significant epide-
miological evidence that has shown that smoking cessation re-
duces morbidity and mortality from CHD.
7,8
Although the underlying mechanism is not clear, Kong et al.
9 
suggested that the consequent increase in hepatic lipase activ-
ity associated with smoking may in turn lead to increased lip-
id accumulation in the arterial wall and may represent one 
mechanism whereby smoking further increases the risk of car-
diovascular disease in Type 2 diabetic subjects.
Smoking has also been shown to be associated with insulin 
resistance in both non-diabetic
10 and Type 2 diabetic subjects,
11 
with impaired oral fat tolerance,
12 impaired intravascular lipol-
ysis
13 and dyslipidemia; these patients are characterized by an 150  Psychiatry Investig 2011;8:149-154
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atherogenic lipoprotein phenotype, with increased triglycer-
ide (TG) and low high density lipoprotein cholesterol (HDL-C) 
concentrations, and high levels of low density lipoprotein cho-
lesterol (LDL-C).
14,15
Whether smokers have worse lipid profiles than non-smok-
ers is controversial. A meta-analysis of 54 cross-sectional stud-
ies with respect to the association of lipid profiles and cigarette 
smoking status revealed that smokers had higher serum con-
centrations of total cholesterol (TC) (3.0%), TG (9.1%), very-
low-density lipoprotein cholesterol (10.4%), and LDL-C (1.7%), 
and lower serum concentrations of HDL-C (5.7%) and apoli-
poprotein A1 (4.2%) than nonsmokers. In addition, a meta-an-
alysis of 27 prospective studies, on the effects of smoking ces-
sation on lipid profiles revealed that smoking cessation 
significantly increased the level of HDL-C but not of TC, LDL-
C, or TG.
16 However, there is limited information available 
regarding the effect of smoking cessation on blood glucose 
control and lipid profiles. Therefore, the changes in blood 
glucose control, lipid profiles, and insulin resistance-associated 
hormones both before and after 2-months of smoking cessa-
tion in Korean male smokers were examined. 
METHODS
Subjects
Twenty male volunteers 28-52 years (mean age of 39 years) 
were enrolled from among the hospital staff at the Bucheon St. 
Mary’s hospital at The Catholic University of Korea via adver-
tisements in the hospital newspapers and website. All of the 
participants fulfilled the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 
criteria for nicotine dependence. The DSM-IV-TR diagnoses 
were determined by two board-certified psychiatrists. All par-
ticipants abstained from illegal drugs and other medications 
and none had mental or physical disorders except for nicotine 
dependence. None of the healthy volunteers had a family histo-
ry of psychiatric illness or medical problems. As a part of the 
initial clinical evaluation, all of the smokers were asked to com-
plete baseline questionnaires requesting detailed information 
regarding demographics and smoking-related clinical variables. 
The severity of nicotine dependence was evaluated by the Fag-
erström Test for Nicotine Dependence (FTND).
17 In order to 
minimize the influence of alcohol and caffeine on the lipid pro-
file, all participants were instructed not to drink more than five 
standard alcoholic drinks a week and one cup of coffee per day, 
and not to change their eating habits during the study period. 
None of the participants were diabetic (fasting glucose <126 
mg/dL) at baseline. Throughout the study period, all subjects 
participated in spontaneous smoking cessation without taking 
medication or nicotine replacement therapy.
Smoking abstinence
During the study period, smoking abstinence was evaluated 
through self-report and urine cotinine levels. The self-report 
was assessed based on the responses to the question Have you 
quit smoking since you enrolled in this study? The urine coti-
nine levels of all subjects were monitored three times: before 
cessation, one month after, and two months after smoking ces-
sation. Urinary samples were obtained without prior warning. 
The urine cotinine levels were measured by a urinary cotinine 
immunoassay dipstick (Nicometer, Jant Pharmaceutical, CA, 
USA). Among 20 participants, 12 smokers succeeded in quit-
ting smoking (validated by a urine cotinine level ≤40 ng/mL) 
and eight smokers failed. Therefore, only the 12 successful in-
dividuals were analyzed. 
Written informed consent was obtained from each subject 
after they had been given a complete explanation of the study. 
The protocol was approved by the Bucheon St. Mary’s Hospital 
ethics committee of the Catholic University of Korea and all 
procedures conformed to the Helsinki Declaration of 1975, as 
revised in 1983.
Laboratory test for blood glucose control, lipid profiles 
and other variables
Blood was drawn from the participants twice, at baseline and 
2 months after smoking cessation. At 7:00 a.m., following an 
overnight fast, a sample of blood was collected from all subjects 
to measure the plasma glucose, HDL-C, LDL-C, TC, TG, total 
protein and albumin levels. The plasma glucose, TC, TG, HDL-
C, and LDL-C levels were analyzed using enzymatic techniques 
(Choongwae Pharma., CO., Seoul, Korea) with a Hitachi 7600-
110 analyzer. Thyroid stimulating hormone (TSH) concentra-
tions were analyzed by immunoradiometric assay using an IR-
MA-mat TSH (IZOTOP, The Institute of Isotopes Co., Ltd., 
Budapest, Hungary) with RIA-mat-280 equipment. Triiodo-
thyronine (T3) levels were analyzed using RIA-mat-280 equip-
ment with the RIA-mat-T3 (Diasorin, Stillwater, USA). Free 
thyroxine (free T4) levels were analyzed using RIA-mat-280 
equipment with the RIA-FT4 (Immunotech, Radiova, Prague, 
Czech Republic). Growth hormone levels were analyzed using 
immunoradiometric assay techniques (Daiichi,Tokyo, Japan) 
in a 1,470 wizard γ-counter. Somatomedin–C levels were ana-
lyzed by radioimmunoassay (BioSource Europe S.A., Belgium) 
in a 1,470 wizard γ-counter. Adrenocorticotropic hormone 
(ACTH) levels were measured by immunoradiometric assay, 
mixing samples with ELSA-ACTH (CIS bio international, Gif-
sur-Yvette Cedex, France) in a 1,470 wizard γ-counter.
Insulin concentrations were analyzed by immunoradiomet-
ric assay (TFB, Tokyo, Japan). Plasma glucose levels were ana-
lyzed using a Roche/Hitachi Modular P analyzer by mixing 
samples with Gluco-quant Glucose/HK (Roche Diagnostics, SS Lee et al. 
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Indianapolis, IN., USA). Epinephrine, norepinephrine and cor-
tisol were assayed in duplicate by radioimmunoassay using 
commercial kits (BioSource Europe S.A., Belgium).
Body composition was analyzed using the Inbody 720 (Bio-
space. CO., Ltd., Seoul, Korea). All body composition parame-
ters such as the body mass index (BMI), body fat mass, waist 
hip ratio and skeletal muscle mass were compared at baseline 
to measurements after 2-months of abstinence.
Assessment of insulin activity and insulin secretion 
Using the fasting glucose and insulin data obtained, the Qu-
antitative Insulin Sensitivity Check Index (QUICKI) and the 
Homeostasis Model Assessment-Insulin Resistance (HOMA-
IR) were used to calculate insulin activity. Insulin secretion was 
assessed by the Homeostasis Model Assessment β-cell func-
tion (HOMA-β) from data obtained while in a fasting state.
Statistical analysis
The data were analyzed by nonparametric tests using SPSS 
12.0 for Windows (SPSS Inc., Chicago, IL. USA). The Wilcox-
on signed rank test was used to analyze the difference in the 
measures both before and after abstinence. A p-value lower 
than 0.05 was considered significant.
RESULTS
Epidemiological data
The mean age of the subjects was 39.0±7.8, with a range of 
28-52 years of age. The mean age that the subjects began smok-
ing was 18.6±1.7 with a range of 17-22 years of age. The mean 
number of cigarettes consumed per day was 19.3±1.7. The 
mean score for the FTND was 2.8±1.7.
Body compositional changes
Body weight (p=0.029) and waist circumference (p=0.020) 
increased during the two months of smoking cessation. Body 
fat composition increased more than muscle (p=0.013) (Ta-
ble 1).
Changes in the lipid profiles
LDL-C levels decreased significantly (p=0.028) after smok-
ing cessation; however, changes in HDL-C, TC and TG were 
not significant (Table 1). 
Effects on insulin resistance and insulin secretion
During smoking cessation, both HOMA-β and HOMA-IR 
exhibited a significant increase while the QUICKI showed a 
significant decrease (p=0.047, p=0.005 and p=0.005 respective-
ly). Overall, the insulin resistance and secretion increased and 
the insulin sensitivity decreased (Table 1, Figures 1 and 2). 
Effects on thyroid hormone and other hormones
The data did not reveal any effects from short–term smoking 
abstinence on thyroid hormones; however, the T3 levels de-
creased (p=0.005) and the cortisol levels increased significant-
ly (p=0.047) (Table 1). 
DISCUSSION
Previous studies have reported that smoking is associated 
with increased blood glucose concentrations, insulin resistance 
and impaired insulin sensitivity.
9,18-20 Blood glucose levels are 
affected by diet. However, smoking has been shown to have 
long-term effects on glucose homeostasis in men and women 
without diabetes, even after adjustment for dietary factors.
21 
Cigarette smoking and nicotine administration increase the 
circulating levels of antagonistic insulin hormones (i.e., cate-
cholamines, cortisol, and growth gormone).
22,23 It is possible 
that nicotine, via these mechanisms, impairs insulin sensitivity, 
directly and indirectly.
24 Cessation of smoking increases insu-
lin sensitivity and normalizes insulin resistance in subjects with 
and without diabetes, despite an increase in the BMI following 
smoking cessation.
25,26
The results of this study showed that insulin resistance in-
creased and insulin sensitivity decreased despite smoking ces-
sation. This might have been due to weight gain, increased fat 
composition and increased cortisol after smoking cessation or 
the short duration of smoking cessation. After an extended 
time of smoking cessation, insulin resistance may decrease and 
insulin sensitivity may increase.
27
In addition, the results of this study showed that during 
smoking cessation, insulin secretion increased more than dur-
ing smoking. High beta cell activity, after smoking cessation, is 
not consistent with the findings of some prior studies.
27,28 The 
likely explanation for this finding is the compensation of beta 
cells for insulin resistance. 
Smoking was positively associated with LDL-C in males of 
European, but not of African descent.
29 It was also reported, in 
a longitudinal observational study during early adulthood, that 
white male and female smokers had a larger increase in their 
LDL-C compared to nonsmokers, and black female smokers 
had an inverse association with the LDL-C levels.
30 It was dem-
onstrated, in a cross-sectional observational study, that the 
HDL-C levels were lower and the triglyceride levels were hig-
her in female as well as male smokers compared to nonsmok-
ers in the Japanese.
31 However, smoking was not related to the 
levels of the total cholesterol or the LDL-C in Singapore.
32
The biological mechanisms explaining the effect of smoking 
on lipid metabolism have not been fully elucidated. Some lab-
oratories have demonstrated that hepatic lipase is increased 
in smokers,
9 and others have demonstrated no difference be-152  Psychiatry Investig 2011;8:149-154
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tween smokers and nonsmokers,
33 and even decreased levels 
of hepatic lipase in smokers.
34 Hepatic lipase has been shown to 
be activated in smokers, and the lectin:cholesterol acyl trans-
ferase activity has been shown to be unchanged
35 or decreased
33 
compared to nonsmokers. Plasma cholesterol ester transfer 
protein activity has been shown to be marginally decreased in 
smokers in one study
33 and increased in another.
35 Plasma 
post-heparin lipoprotein lipase activity is unchanged in smok-
ers and nonsmokers in some studies
34,36 and was increased in 
smokers in another study.
33 As these findings suggest, there are 
significant inconsistencies in the findings of studies.
Regardless of the conflicting study results, plasma enzymes 
appear to be involved in the metabolism of triglycerides and 
HDL-C, which are potentially affected by smoking. It is possi-
ble that the effect of smoking on these enzymes is dependent 
on numerous factors including: gender, age, genetic back-
ground, and the ethnicity of smokers. Other important factors 
include dietary habits, physical activity, and lifestyle as well as 
differences in public health awareness.
31
There have been very few studies examining the effect of 
smoking cessation on lipid profiles. In addition, the reported 
study results have been inconsistent. A meta-analysis of 27 
studies concluded that HDL-C was significantly increased but 
that the levels of TC, LDL-C, and TG did not change signifi-
cantly after smoking cessation.
16 Quitting smoking led to an in-
crease in HDL-C but no change in the LDL-C.
37 There was also 
Table 1. Profile of participants before and after smoking cessation
Baseline (A) (N=12)
After smoking
Cessation (B) (N=12)
B - A
p-value
Mean (S.D) Mean (S.D) Mean (S.D)
Weight (kg) 068.58 (9.04) 069.49 (9.05) -00.83 (1.02) 0.029*
BMI (kg/m
2) 023.86 (3.53) 024.20 (3.57) -00.32 (0.34) 0.014*
WHR 000.87 (0.45) 000.88 (0.42) -00.01 (0.01) 0.020*
BFM (kg) 014.95 (6.31) 015.73 (6.31) -00.72 (0.79) 0.013*
SMM (kg) 030.17 (2.60) 030.23 (2.62) -00.05 (0.43) 0.753
FPG (mg/dL) 089.83 (11.37) 097.91 (16.68) -08.08 (16.03) 0.036*
Insulin (μU/mL) 008.15 (2.26) 013.49 (6.68) -05.34 (6.93) 0.005*
HOMA-IR 001.83 (0.63) 003.40 (2.14) -01.57 (2.24) 0.005*
HOMA-β 122.12 (45.59) 146.91 (60.83) -24.79 (40.63) 0.047*
QUICKI 000.35 (0.16) 000.33 (0.02) 0-0.22 (0.22) 0.005*
Total Protein (g/dL) 007.28 (0.36) 006.96 (0.35) 0-0.32 (0.26) 0.007*
Albumin (g/dL) 004.83 (0.23) 004.50 (0.26) 0-0.33 (0.23) 0.003*
TC (mg/dL) 211.46 (33.75) 208.06 (41.67) 0-3.40 (15.60) 0.508
TG (mg/dL) 142.67 (59.35) 180.92 (133.21) 038.25 (107.86) 0.445
HDL-C (mg/dL) 061.01 (16.82) 060.96 (23.15) 0-0.05 (14.31) 0.284
LDL-C (mg/dL) 121.92 (32.86) 110.92 (29.53) -11.00 (14.49) 0.028*
ACTH (pg/mL) 042.69 (12.86) 043.11 (23.55) -00.42 (20.56) 0.575
GH (ng/mL) 000.44 (0.36) 000.49 (0.48) -0-0.05 (0.40) 0.594
Somatomedin-C (ng/mL) 471.25 (97.74) 427.10 (121.13) --40.47 (120.69) 0.203
Free T4 (ng/dL) 001.36 (0.18) 001.38 (0.15) -0-0.02 (0.12) 0.541
T3 (ng/dL) 174.84 (15.15) 166.11 (16.04) 0-8.72 (9.34) 0.005*
TSH (mIU/mL) 001.67 (0.81) 001.94 (1.30) -00.28 (1.07) 0.799
Cortisol (ug/dL) 011.55 (3.76) 014.93 (5.29) -03.38 (5.09) 0.047*
Epinephrine (pg/mL)  026.07 (17.42) 034.12 (31.99) -08.05 (33.44) 0.575
Norepinephrine (pg/mL) 200.15 (169.93) 116.97 (115.65) -83.17 (183.39) 0.203
P-value was obtained by Wilcoxon signed rank test on differences. *p<0.05. BMI: body mass index, WHR: waist hip ratio, BFM: body fat mass, 
SMM: skeletal muscle mass, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment-insulin resistance, HOMA-β: homeosta-
sis model assessment β-cell function, QUICKI: quantitative insulin sensitivity check index, TC: total cholesterol, TG: triglyceride, HDL-C: high 
density lipoprotein–cholesterol, LDL-C: low density lipoprotein–cholesterol, ACTH: adreno cortico tropic hormone, GH: growth hormone, 
Free T4: free thyroxine, T3: thyronine, TSH: thyroid-stimulating hormoneSS Lee et al. 
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an increase in the resistance of LDL-C to oxidation and not of 
the serum level of LDL-C after smoking cessation.
38
Some possible explanations for the changes in the lipid pro-
file caused by smoking cessation include the following. HDL-C 
normally promotes cholesterol clearance and decreases LDL-C 
oxidation.
39 Since oxidized LDL-C, but not native LDL-C, is 
taken up by macrophages, via a scavenger receptor family, and 
thereby causes the formation of foam cells observed in athero-
sclerotic lesions, oxidative modification of LDL-C is thought 
to be the key process underlying the development of athero-
sclerosis.
38 Smoking might lower the level of HDL by the fol-
lowing: 1) increasing the cholesteryl ester transfer protein; 2) 
reducing lecithin cholesterol acyltransferase activity; 3) affect-
ing apo-1 synthesis; and 4) increasing TG.
40 These unfavorable 
conditions (i.e., decreased HDL-C) may be restored to favor-
able levels by smoking cessation. Another mechanism by 
which smoking could reduce HDL-C, increase triglycerides, 
and increase plasminogen activator inhibitor-1 is through in-
sulin resistance.
41,42
In this study, LDL-C levels decreased after smoking cessa-
tion, suggesting that the beneficial effects of smoking cessa-
tion; however, changes in HDL-C and TC were not significant. 
The discrepancy between the levels of cholesterol in this study 
compared to previous studies may be due to the fact that sub-
jects that stopped smoking included those with recent and 
long-term cessation, resulting in the confounding of short- and 
long-term changes in the cholesterol levels. 
The limitations of this study include the following. First, the 
sample size was relatively small. Future studies will need to re-
cruit more subjects in order to increase the statistical power of 
this research. Second, only males were recruited for this study, 
so the findings are not generalizable to women. Gender differ-
ences in smoking behaviors and metabolic brain responses to 
nicotine have been reported.
43-45 Third, we analyzed 12 smok-
ers succeeded in quitting smoking instead of nonsmokers or 
smokers who couldn’t quit smoking as control group. Fourth, 
there are some confounding factors affecting the results. As 
mentioned earlier, there are many differences between smokers 
and non-smokers with regard to background characteristics, 
such as diet, exercise, obesity, and drinking alcohol.
3,4,31 In ad-
dition, we did not evaluate the change of appetite during smok-
ing abstinence so we could not exclude the effect of appetite on 
weight gain. Fifth, the duration of smoking cessation was only 
2-months. A prolonged period of cigarette smoking cessation 
may be necessary to determine the effects of the change in blood 
glucose control and lipid profiles.
5,25,26
Despite these limitations, the strength of the present study is 
that the findings can be used to guide clinicians and patients in 
smoking cessation. It is important to include education about 
weight control with diet and regular exercise (both aerobic and 
anaerobic) for blood glucose control in smoking cessation pro-
grams.  
In conclusion, the results of this study showed that during 
the initial stage of smoking cessation, insulin resistance in-
creased and insulin sensitivity decreased due to elevated body 
weight and fat composition. Therefore, weight control includ-
ing diet control and physical exercise is necessary as part of 
smoking cessation programs. In the short-term, the positive 
effects of quitting smoking might not be immediately obvious. 
Therefore, further longitudinal studies including the control of 
the BMI, physical activity and other confounding risk factors 
such as medical history and alcohol consumption are needed 
to evaluate the effects of smoking cessation on physical and 
laboratory findings. 
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